| Literature DB >> 25548632 |
Kazuhiro Omori1, Yoshihisa Hanayama2, Koji Naruishi1, Kentaro Akiyama3, Hiroshi Maeda1, Fumio Otsuka2, Shogo Takashiba1.
Abstract
It has been suggested that vitamin C deficiency/scurvy is associated with gingival inflammatory changes; however, the disorder is very infrequently encountered in the modern era. Here, we report a case of extensive gingival overgrowth caused by vitamin C deficiency associated with metabolic syndrome and severe periodontal infection.Entities:
Keywords: Gingival overgrowth; metabolic syndrome; periodontal infection; supplementation of ascorbic acid; vitamin C deficiency
Year: 2014 PMID: 25548632 PMCID: PMC4270712 DOI: 10.1002/ccr3.114
Source DB: PubMed Journal: Clin Case Rep ISSN: 2050-0904
Figure 1Periodontal images of the patient taken before periodontal treatment. (A) Extensive gingival overgrowth with severe periodontal inflammation was observed in the maxillary and mandibular arches at the first visit (July, 2008), (B) treatment protocol.
Figure 2Periodontal examination and full mouth X-ray images taken of the patient before periodontal treatment. (A) The periodontal chart at the first visit revealed pocket probing depths that were significantly higher than normal with a rate of bleeding on probing (BOP)-positive sites of 98%, (B) radiographic evaluation revealed severe bone loss around the incisors and maxillary molars due to severe periodontal infection and traumatic occlusion (July, 2008).
Periodontal bacteria identified by quantitative real-time PCR at the first visit
| Sampling site | Probing depth | Total bacteria | Aa | Pg | Pi |
|---|---|---|---|---|---|
| #9, BM | 8 mm | 1.13 × 105 | 6.75 × 102 | 3.72 × 102 | 2.60 × 103 |
| #19, BM | 8 mm | 1.61 × 106 | 4.08 | 1.70 × 103 | 5.21 × 105 |
| #4, BM | 7 mm | 3.33 × 105 | 1.69 × 104 | 1.28 × 102 | 3.57 × 104 |
A periodontal microbiological examination was performed using quantitative real-time PCR, as described previously [7]. The following pathogens were detected and the associated data are shown as DNA copies/sample. Aa, Aggregatibactor actinomycetemcomitans; Pg, Porphyromonas gingivalis; Pi, Prevotella intermedia; BM, buccal mesial.
Changes in laboratory parameters
| Parameter | Unit | First visit (September, 2008) | Whole-body screening (September, 2011) | After vitamin C supplementation (April, 2012) | Present (January, 2014) | Standard level |
|---|---|---|---|---|---|---|
| WBC | 103/ | 7.62 | 7.98 | 6.47 | 6.54 | 3.50–8.50 |
| RBC | 106/ | 5.33 | 5.50 | 5.30 | 5.33 | 4.30–5.70 |
| Hb | g/dL | 16.2 | 16.1 | 16.0 | 15.9 | 13.5–17.0 |
| Ht | % | 47.5 | 49.0 | 48.2 | 47.5 | 40.0–50.0 |
| PLT | 103/ | 317 | 301 | 314 | 307 | 150–350 |
| Alb | g/dL | 4.4 | 4.5 | 4.5 | 4.1 | 3.9–4.9 |
| TTT | U | 1.5 | 2.2 | 0.2–5.3 | ||
| ZTT | U | 10.8 | 11.9 | 3.8–14.9 | ||
| Total bilirubin | mg/dL | 1.10 | 1.56 | 0.33–1.28 | ||
| Direct bilirubin | mg/dL | 0.22 | 0.30 | 0.08–0.28 | ||
| AST | IU/L | 26 | 40 | 43 | 19 | 10–35 |
| ALT | IU/L | 20 | 40 | 51 | 20 | 7–42 |
| ALP | IU/L | 249 | 110–360 | |||
| LAP | IU/L | 101 | 118 | 102 | 81 | 28–75 |
| IU/L | 129 | 207 | 140 | 95 | 5–60 | |
| CHE | IU/L | 501 | 558 | 548 | 484 | 168–470 |
| LD | IU/L | 164 | 211 | 182 | 171 | 120–240 |
| Na | mmol/L | 140 | 140 | 138 | 138 | 136–144 |
| K | mmol/L | 4.6 | 4.1 | 4.0 | 4.2 | 3.7–4.9 |
| Cl | mmol/L | 106 | 103 | 105 | 103 | 102–110 |
| Ca | mg/dL | 9.7 | 9.6 | 9.2 | 9.2 | 8.6–10.1 |
| Mg | mg/dL | 2.1 | 2.0–2.5 | |||
| Fe | 129 | 80–140 | ||||
| Ferritin | ng/dL | 262.2 | 39.9–465.0 | |||
| Cu | 133 | 78–141 | ||||
| Zn | 100 | 80–130 | ||||
| UN | mg/dL | 12.7 | 11.1 | 13.9 | 13.5 | 8.1–22.0 |
| Cr | mg/dL | 0.88 | 0.85 | 0.84 | 0.86 | 0.6–1.1 |
| UA | mg/dL | 7.0 | 7.1 | 4.1 | 4.2 | 3.5–7.0 |
| UN/Cr | 14.8 | 13.1 | 16.5 | 15.7 | 10.2–27.6 | |
| CK | IU/L | 124 | 41–258 | |||
| Amylase | IU/L | 66 | 38–125 | |||
| TG | mg/dL | 171 | 271 | 343 | 40–150 | |
| T-CHO | mg/dL | 259 | 273 | 130–220 | ||
| HDL-C | mg/dL | 92 | 74 | 83 | 41–85 | |
| LDL-C | mg/dL | 157 | 144 | 141 | 70–139 | |
| LDL/HDL | 1.7 | 1.9 | 1.7 | |||
| HbA1c (NGSP) | % | 6.3 | 6.4 | 6.3 | 4.7–6.2 | |
| Albumin | % | 63.2 | 60.9–71.3 | |||
| % | 2.5 | 1.8–2.7 | ||||
| % | 7.5 | 5.9–8.5 | ||||
| % | 11.0 | 6.9–10.5 | ||||
| % | 15.8 | 11.0–21.2 | ||||
| Albumin/globulin | 1.7 | 1.50–2.43 | ||||
| hs-CRP | mg/dL | 0.04 | 0.31 | 0.08 | 0.10 | 0.00–0.30 |
| IgG | mg/dL | 1379.3 | 870–1818 | |||
| IgA | mg/dL | 353.8 | 110–424 | |||
| IgM | mg/dL | 81.6 | 31–252 | |||
| CH50 | U/ml | 39 | 30–50 | |||
| C3 | mg/dL | 133.1 | 65–135 | |||
| C4 | mg/dL | 28.7 | 13–35 | |||
| Vitamin C | 3.8 | 8.1 | 5.6–15.6 | |||
| Rheumatoid factor | IU/mL | 1.5 | 0.0–16.0 | |||
| IgG4 | mg/dL | 17.5 | 4.8–105.0 | |||
| HTLV-I Ab | Negative | Negative | ||||
| HBV Ag | Negative | Negative | ||||
| HBV Ab | Negative | Negative | ||||
| HCV Ab | Negative | Negative | ||||
| HIV Ab | Negative | Negative |
Blank data are not measured. WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; Ht, hematocrit; PLT, platelets; Alb, albumin; TTT, thymol turbidity test; ZTT, zinc sulfate turbidity test; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LD, lactate dehydrogenase; UN, urea nitrogen; Cr, creatinine; UA, uric acid; CK, creatinine kinase; hs-CRP, high-sensitivity C-reactive protein; IgG, immunoglobulin G; IgM, immunoglobulin M; IgA immunoglobulin A; IgG4, immunoglobulin G4; HTLV-1 Ab: anti-human T-cell leukemia virus type 1 antibody; HBV Ag, hepatitis B virus surface antigen; HBV Ab, anti-hepatitis B virus antibody; HCV Ab, anti-hepatitis C virus antibody; HIV Ab, anti-human immunodeficiency virus type 1 and 2 antibody; BMI, body mass index.
Above upper limit.
Below lower limit.
Figure 3Microscopic evaluation of the specimen taken from the patient showed hyperplasia of the epithelial region and extended epithelial rete ridges in addition to the infiltration of severe inflammatory cells (primarily plasma cells) in the connective tissue. No dense, mature, parallel collagen bundles were observed nor was there any evidence of tumor proliferation or viral or fungal infection. Original magnification = 40 × ; bar = 500 μm, =400 × ; bar = 50 μm, respectively.
Figure 4Reevaluation after the first gingivectomy. (A) Periodontal images, (B) full mouth X-ray images, (C) periodontal chart (April, 2010).
Figure 5Periodontal images taken before and after ascorbic acid supplementation. (A) Recurrent gingival overgrowth observed after the second gingivectomy and before ascorbic acid supplementation (September, 2011), (B) images taken after 9 months of ascorbic acid supplementation (June, 2012). The white arrows indicate typical sites of recurrent gingival overgrowth.
Figure 6Periodontal status of the patient after periodontal treatment and ascorbic acid supplementation. (A) recent periodontal images revealed no recurrence of gingival overgrowth (January, 2014), (B) periodontal chart revealed a significant reduction in pocket probing depths and in the number of BOP-positive sites compared to the first visit, (C) radiographic evaluation revealed that a stable alveolar bone level was maintained during supportive periodontal therapy (October, 2013).